Abbott Laboratories
Abbott Laboratories Announces Proposed Settlement in Shareholder Derivative Lawsuit
Summary
Abbott Laboratories has announced a proposed settlement in a shareholder derivative lawsuit related to the company's infant formula products. The lawsuit, which has been pending in the United States District Court for the Northern District of Illinois, alleges breaches of fiduciary duty and violations of federal securities laws by certain current and former directors and officers of Abbott. The proposed settlement, if approved by the court, will dismiss the lawsuit with prejudice and include corporate governance reforms and enhanced internal reporting and oversight framework for legal and regulatory compliance. A final settlement hearing is scheduled for June 4, 2026.
Profitelligence Alerts
Get alerts for ABT
Be first to know when Abbott Laboratories files with the SEC.
Filing Categories
Advertisement
About Abbott Laboratories
Abbott Laboratories, a globally renowned company, specializes in the development and production of healthcare and medical products. Founded in 1888 and headquartered in Abbott Park, Illinois, Abbott is a pivotal entity in the healthcare sector. The company provides essential products spanning diagnostics, medical devices, nutritional products, and branded generic pharmaceuticals. Notably, Abbott's extensive diagnostic solutions include immunoassays and molecular diagnostics, crucial for medical testing and healthcare management. Its medical devices division produces cardiovascular and neuromodulation products, enhancing patient care across diverse medical practices. Abbott’s nutritional segment, featuring well-known brands like Similac and Ensure, supports health and wellness across various demographics. Serving markets globally, Abbott Laboratories plays a critical role in advancing healthcare infrastructure and delivering innovative solutions that address evolving health challenges worldwide. As a significant player in the life sciences field, Abbott's contributions significantly influence patient outcomes and healthcare delivery systems.
Official SEC Documents
Advertisement